MaveriX Oncology Overview

  • Founded

  • 2014

Founded
  • Status

  • Private

  • Employees

  • 2

Employees
  • Latest Deal Type

  • Series A

  • Latest Deal Amount

  • $6.5M

  • Investors

  • 2

MaveriX Oncology General Information

Description

Developer of novel immunotherapies designed to bridge the therapeutic gap in cancer treatment The company's immunotherapies leverage unexploited insights into cancer and immune cell metabolism within the tumor microenvironment which are common to all cancers, enabling medical practitioners to selectively deliver the tumor cell killing benefits of chemotherapy while generating a strong immune response to attack a wide range of cancers.

Contact Information

Website
www.maverixoncology.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Primary Office
  • 435 Middlefield Road
  • Palo Alto, CA 94301
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MaveriX Oncology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series A) 14-Oct-2019 $6.5M 00.00 0000 Completed Clinical Trials - Phase 1
1. Angel (individual) 02-Jun-2016 000000 Completed Startup
To view MaveriX Oncology’s complete valuation and funding history, request access »

MaveriX Oncology Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view MaveriX Oncology’s complete cap table history, request access »

MaveriX Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel immunotherapies designed to bridge the therapeutic gap in cancer treatment The company's immunotherap
Drug Discovery
Palo Alto, CA
2 As of 2022
00.00
000 0000-00-00
00000000000 00.00

000000

sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna al
0000 00000000
San Diego, CA
000 As of 0000
00000
0000000000 0 00000

00000

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
0000 000000000
South San Francisco, CA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MaveriX Oncology Competitors (78)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Rakuten Medical Venture Capital-Backed San Diego, CA 000 00000 0000000000 0 00000
00000 000000000000 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
00000000 Venture Capital-Backed Middleton, WI 00 000.00 0000000000 0 000.00
000000-000 0000000 Venture Capital-Backed Palo Alto, CA 00 00000 0000000000 00000
00000 00000000 Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
You’re viewing 5 of 78 competitors. Get the full list »

MaveriX Oncology Patents

  • 8

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

MaveriX Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3746134-A1 Small molecule drug conjugates of gemcitabine monophosphate Pending 02-Feb-2018 000000000
AU-2019216514-A1 Novel small molecule drug conjugates of gemcitabine derivatives Pending 02-Feb-2018 000000000
CA-3090272-A1 Novel small molecule drug conjugates of gemcitabine derivatives Pending 02-Feb-2018 000000000
EP-3746133-A1 Novel small molecule drug conjugates of gemcitabine derivatives Pending 02-Feb-2018 000000000
AU-2019216531-A1 Small molecule drug conjugates of gemcitabine monophosphate Pending 02-Feb-2018 C07H19/10
To view MaveriX Oncology’s complete patent history, request access »

MaveriX Oncology Executive Team (3)

Name Title Board Seat Contact Info
Steven Everett Ph.D Co-Founder, President, Chief Executive Officer, Chief Scientific Officer & Board Member
Chris Bowers Chief Operating Officer
You’re viewing 2 of 3 executive team members. Get the full list »

MaveriX Oncology Board Members (4)

Name Representing Role Since
Kim Nearing MaveriX Oncology Board Member 000 0000
Norbert Prenzel MaveriX Oncology Board Member 000 0000
Riccardo Panicucci Ph.D MaveriX Oncology Board Member 000 0000
Steven Everett Ph.D MaveriX Oncology Co-Founder, President, Chief Executive Officer, Chief Scientific Officer & Board Member 000 0000
To view MaveriX Oncology’s complete board members history, request access »

MaveriX Oncology Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MaveriX Oncology Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
PPF Group PE/Buyout Minority 000 0000 000000 0
SOTIO PE-Backed Company Minority 000 0000 000000 0
To view MaveriX Oncology’s complete investors history, request access »

Ready to get started?

Request a free trial